Exparel Injection Effect on Postoperative Opioid Usage

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Sep 9, 2019

Keywords

ClinConnect Summary

This study is asking whether adding Exparel (a long-acting local anesthetic) given during thyroid or parathyroid surgery can reduce the need for opioid pain medicines in the two weeks after surgery. Participants will be randomly assigned to one of three approaches to local anesthesia: (1) the current practice of lidocaine with epinephrine before the cut, (2) preincision bupivacaine with epinephrine, or (3) preincision lidocaine with epinephrine plus Exparel given after the incision. Researchers will track daily pain and any opioid use after surgery.

To be eligible, adults 18 and older must be planning thyroid or parathyroid surgery and be able to read and understand English. People with a history of opioid abuse or true allergies to local anesthetics or opioids are not eligible. You won’t know which treatment group you’re in during the consent process, and surgery will proceed as planned with the assigned anesthesia plan. After surgery, you’ll record your pain level and any medications used for about two weeks, either in a pain diary or through your medical records, and you’ll have a follow-up visit to review how you did. The trial is run by the University of Missouri-Columbia and is currently enrolling by invitation, with completion expected around mid-2025.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over the age of 18 years Patients requiring parathyroid/thyroid surgery based on the standard of care English as primary language
• Exclusion Criteria:
• • Patients under the age of 18 years Patients with previous history of opioid abuse Patients with a true allergy to any local anesthetic Patients with a true allergy to any opioid